Vivos Therapeutics, Inc.
VVOS
$0.80
$0.022.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.41% | 75.73% | -5.77% | -11.79% | 13.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.41% | 75.73% | -5.77% | -11.79% | 13.85% |
| Cost of Revenue | -47.78% | 86.50% | 21.88% | 1.69% | 38.14% |
| Gross Profit | 42.49% | 68.68% | -20.41% | -22.10% | 0.38% |
| SG&A Expenses | 87.60% | 71.47% | 50.14% | -5.85% | -21.64% |
| Depreciation & Amortization | 206.94% | 163.01% | 111.03% | 21.23% | -3.36% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.92% | 77.05% | 44.99% | -3.75% | -11.88% |
| Operating Income | -127.44% | -78.98% | -151.29% | -3.51% | 32.11% |
| Income Before Tax | -145.99% | -106.42% | -159.74% | -2.68% | 33.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -145.99% | -106.42% | -159.74% | -2.68% | 33.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -143.86% | -106.42% | -159.74% | -2.68% | 33.62% |
| EBIT | -127.44% | -78.98% | -151.29% | -3.51% | 32.11% |
| EBITDA | -123.14% | -74.07% | -154.55% | -2.80% | 33.18% |
| EPS Basic | -41.95% | -24.56% | 7.71% | 72.43% | 86.97% |
| Normalized Basic EPS | -41.22% | -24.51% | 7.71% | 72.42% | 86.97% |
| EPS Diluted | -41.95% | -24.56% | 7.71% | 72.43% | 86.97% |
| Normalized Diluted EPS | -41.22% | -24.51% | 7.71% | 72.42% | 86.97% |
| Average Basic Shares Outstanding | 71.76% | 65.73% | 181.48% | 272.38% | 409.47% |
| Average Diluted Shares Outstanding | 71.76% | 65.73% | 181.48% | 272.38% | 409.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |